July 9, 2018 - ZikaPLAN’s NEURO-ZIKA neurological manifestations working group leader, the University of Liverpool, has been working with another working group member, Fiocruz, and the Brazilian Ministry of Health, the Brazilian charities ‘Uniao de Maes dos Anjos-UMA’ (Recife), ‘Associação ... Read more
July 3, 2018 - NEURO-ZIKA pathogenesis work in ZikaPLAN is differentiating autoimmune versus direct neuropathic phenomena of ZIKV to impact both clinical care and basic understanding of disease. Read more
June 27, 2018 - Over 80% of the world’s population is at risk from vector-borne diseases, yet no single, all-encompassing resource for the researchers and health workers involved in vector-borne disease control exists today. The aim of the Global Vector ... Read more
June 14, 2018 - ZIKAlliance, ZikaPLAN, ZIKAction, and ZIKAVAX - the four EU-funded consortia - participated and presented their research findings at the International Symposium on Zika Virus Research, held in Marseille, France, between 4 and 6 June 2018. Importantly, ... Read more
Dr. Ralph Huits et al - Travel Medicine and Infectious Disease, September 12, 2018
Zika virus (ZIKV) infection is of concern to travellers because of potential sexual transmission and adverse pregnancy outcomes. In this article, the authors describe their experience in diagnosing ZIKV in travellers returning from endemic territories.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.